QNCX Phase 2 readout: a negative outcome, -13.5%

On May 18, 2026, Quince Therapeutics, Inc. reached its Phase 2 readout. The result was a negative outcome, and the stock moved -13.5% in the window around the event. It had already run -16.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.